Trial Profile

ANRS 173 ALTAR A randomized, open-label, phase III trial comparing a dual nucleoside analogues strategy preceded by an induction period with an integrase inhibitor based triple therapy to an immediate two-drug strategy with dolutegravir plus lamivudine in ART naïve people living with HIV with viral load < 50 000 cp/mL and CD4 cells >300/mm3

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 06 Sep 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary) ; Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary) ; Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat (Primary) ; Emtricitabine/tenofovir alafenamide (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Raltegravir (Primary) ; Tenofovir disoproxil fumarate (Primary) ; Dolutegravir; Lamivudine
Indications HIV-1 infections
Focus Therapeutic Use
Acronyms ALTAR

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com